D. Lavanchy, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, Journal of Viral Hepatitis, vol.34, issue.2, pp.97-107, 2004.
DOI : 10.1056/NEJM200012073432302

C. Shepard, L. Finelli, and M. Alter, Global epidemiology of hepatitis C virus infection, The Lancet Infectious Diseases, vol.5, issue.9, pp.558-67, 2005.
DOI : 10.1016/S1473-3099(05)70216-4

D. Parkin, The global health burden of infection-associated cancers in the year 2002, International Journal of Cancer, vol.291, issue.12, pp.3030-3074, 2006.
DOI : 10.1002/ijc.21731

W. Robinson, D. Clayton, and R. Greenman, DNA of a human hepatitis B virus candidate, J Virol, vol.14, pp.384-91, 1974.

K. Kidd-ljunggren, Y. Miyakawa, and A. Kidd, Genetic variability in hepatitis B viruses, Journal of General Virology, vol.83, issue.6, pp.1267-80, 2002.
DOI : 10.1099/0022-1317-83-6-1267

S. Schaefer, Hepatitis B virus taxonomy and hepatitis B virus genotypes, World Journal of Gastroenterology, vol.13, issue.1, pp.14-21, 2007.
DOI : 10.3748/wjg.v13.i1.14

C. Chu and Y. Liaw, Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: A longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline, Journal of Hepatology, vol.43, issue.3, pp.411-418, 2005.
DOI : 10.1016/j.jhep.2005.03.018

C. Chu and Y. Liaw, Predictive Factors for Reactivation of Hepatitis B Following Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B, Gastroenterology, vol.133, issue.5, pp.1458-65, 2007.
DOI : 10.1053/j.gastro.2007.08.039

H. Flink, M. Van-zonneveld, B. Hansen, R. De-man, S. Schalm et al., Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype, The American Journal of Gastroenterology, vol.112, issue.3, pp.297-303, 2006.
DOI : 10.1056/NEJMoa040431

M. Funk, D. Rosenberg, and A. Lok, World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants, Journal of Viral Hepatitis, vol.39, issue.1, pp.52-61, 2002.
DOI : 10.1002/(SICI)1096-9071(199909)59:1<14::AID-JMV3>3.0.CO;2-T

C. Grandjacques, P. Pradat, L. Stuyver, M. Chevallier, P. Chevallier et al., Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity, Journal of Hepatology, vol.33, issue.3, pp.430-439, 2000.
DOI : 10.1016/S0168-8278(00)80279-2

S. Schalm, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, Lancet, vol.365, pp.123-132, 2005.

S. Livingston, J. Simonetti, B. Mcmahon, L. Bulkow, K. Hurlburt et al., Hepatitis B Virus Genotypes in Alaska Native People with Hepatocellular Carcinoma: Preponderance of Genotype F, The Journal of Infectious Diseases, vol.195, issue.1, pp.5-11, 2007.
DOI : 10.1086/509894

E. Orito, T. Ichida, H. Sakugawa, M. Sata, N. Horiike et al., Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan, Hepatology, vol.34, issue.3, pp.590-594, 2001.
DOI : 10.1053/jhep.2001.27221

S. Chevaliez and J. Pawlotsky, Editor: Tan S-L . HCV genome and life cycle . Hepatitis C viruses: genome and molecular biology, Horizon Bioscience, pp.5-47, 2006.

P. Simmonds, J. Bukh, C. Combet, G. Deleage, N. Enomoto et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, vol.17, issue.4, pp.962-73, 2005.
DOI : 10.1002/hep.20819
URL : https://hal.archives-ouvertes.fr/hal-00313678

D. Murphy, J. Chamberland, R. Dandavino, and E. Sablon, Hepatitis C Virus Genotype 7, a New Genotype Originating from Central Africa, Journal of Clinical Microbiology, vol.53, issue.3, p.623, 2007.
DOI : 10.1128/JCM.02831-14

A. Ackrill, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med, vol.140, pp.346-55, 2004.

M. Kan and W. Gerlich, Structure and Molecular Virology, Blackwell, 2005.
DOI : 10.1002/9780470987131.ch10

R. Biswas, E. Tabor, C. Hsia, D. Wright, M. Laycock et al., Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection, Transfusion, vol.42, issue.6, pp.788-98, 2003.
DOI : 10.1046/j.1537-2995.2002.00128.x

R. Gibb, G. Nimmo, O. Loughlin-'p, P. Lowe, and D. Drummond, Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection, Journal of Medical Virology, vol.68, issue.4, pp.351-356, 2007.
DOI : 10.1002/jmv.20823

A. Muhlbacher, B. Weber, P. Burgisser, A. Eiras, J. Cabrera et al., Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants, Medical Microbiology and Immunology, vol.ii, issue.Suppl 1, pp.55-64, 2008.
DOI : 10.1007/s00430-007-0059-9

B. Weber, N. Van-der-taelem-brule, A. Berger, F. Simon, M. Geudin et al., Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra, Journal of Virological Methods, vol.135, issue.1, pp.109-126, 2006.
DOI : 10.1016/j.jviromet.2006.02.009

B. Weber, A. Bayer, P. Kirch, V. Schluter, D. Schlieper et al., Improved detection of hepatitis B virus surface antigen by a new rapid automated assay, J Clin Microbiol, vol.37, pp.2639-2686, 1999.

B. Weber, T. Dengler, A. Berger, H. Doerr, and H. Rabenau, Evaluation of Two New Automated Assays for Hepatitis B Virus Surface Antigen (HBsAg) Detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg, Journal of Clinical Microbiology, vol.41, issue.1, pp.135-178, 2003.
DOI : 10.1128/JCM.41.1.135-143.2003

A. Lok and B. Mcmahon, Chronic hepatitis B, Hepatology, vol.34, issue.6, pp.1225-1266, 2001.
DOI : 10.1053/jhep.2001.29401

N. Shukla and M. Poles, Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus, Clinics in Liver Disease, vol.8, issue.2, pp.445-60, 2004.
DOI : 10.1016/j.cld.2004.02.005

T. Berg, M. Von-wagner, S. Nasser, C. Sarrazin, T. Heintges et al., Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin, Gastroenterology, vol.130, issue.4
DOI : 10.1053/j.gastro.2006.02.015

C. Su, Y. Huang, T. Huo, H. Shih, I. Sheen et al., Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients, Gastroenterology, vol.130, issue.6, pp.1625-1660, 2006.
DOI : 10.1053/j.gastro.2006.01.035

S. Akhan, Z. Yulugkural, and H. Vahaboglu, Response to Interferon-Alpha in Chronic Hepatitis B Patients with and without Precore Mutant Strain and Effects on HBsAg Titers, Chemotherapy, vol.53, issue.6, pp.402-408, 2007.
DOI : 10.1159/000109770

H. Chan, V. Wong, A. Tse, C. Tse, A. Chim et al., Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response, Clinical Gastroenterology and Hepatology, vol.5, issue.12, pp.1462-1470, 2007.
DOI : 10.1016/j.cgh.2007.09.005

R. Ozaras, F. Tabak, V. Tahan, R. Ozturk, H. Akin et al., Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment, Digestive Diseases and Sciences, vol.5, issue.1 Suppl, 2008.
DOI : 10.1007/s10620-008-0263-5

G. Fattovich, F. Bortolotti, and F. Donato, Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors, Journal of Hepatology, vol.48, issue.2, pp.335-52, 2008.
DOI : 10.1016/j.jhep.2007.11.011

Y. Liaw, I. Sheen, T. Chen, C. Chu, and C. Pao, Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study, Hepatology, vol.312, issue.4, pp.627-658, 1991.
DOI : 10.1002/hep.1840130403

S. Nam, J. Jung, S. Bae, J. Choi, S. Yoon et al., Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection, The Korean Journal of Internal Medicine, vol.22, issue.2, pp.73-79, 2007.
DOI : 10.3904/kjim.2007.22.2.73

T. Wu, H. Hsu, D. Chen, J. Sheu, I. Su et al., Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma, Journal of Hepatology, vol.4, issue.1, pp.45-51, 1987.
DOI : 10.1016/S0168-8278(87)80008-9

S. Brown, A. Barbara, T. Lambert, and D. Wilson, Spontaneous loss of HBeAg and development of anti-HBe during long-term follow-up of blood donors found to be HBsAg-positive, Br J Biomed Sci, vol.52, pp.106-115, 1995.

A. Lok, E. Heathcote, and J. Hoofnagle, Management of hepatitis B: 2000???Summary of a workshop, Gastroenterology, vol.120, issue.7, pp.1828-53, 2001.
DOI : 10.1053/gast.2001.24839

M. Busch, S. Glynn, S. Stramer, D. Strong, S. Caglioti et al., A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors, Transfusion, vol.14, issue.2, pp.254-64, 2005.
DOI : 10.1089/088922202753472874

N. Coppola, R. Pisapia, C. Marrocco, S. Martini, L. Vatiero et al., Anti-HCV IgG avidity index in acute hepatitis C, Journal of Clinical Virology, vol.40, issue.2, pp.110-115, 2007.
DOI : 10.1016/j.jcv.2007.07.005

U. Hellstrom, S. Sylvan, R. Decker, and A. Sonnerborg, Immunoglobulin M reactivity towards the inununologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection, Journal of Medical Virology, vol.11, issue.4, pp.325-357, 1993.
DOI : 10.1002/jmv.1890390412

F. Negro, H. Troonen, G. Michel, E. Giostra, M. Albrecht et al., Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection, Journal of Virological Methods, vol.60, issue.2, pp.179-82, 1996.
DOI : 10.1016/0166-0934(96)02058-7

E. Sagnelli, N. Coppola, C. Marrocco, G. Coviello, G. Rossi et al., Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation, J Biol Regul Homeost Agents, vol.17, pp.207-217, 2003.

E. Sagnelli, N. Coppola, C. Marrocco, G. Coviello, M. Battaglia et al., Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres, Journal of Hepatology, vol.42, issue.5, pp.646-51, 2005.
DOI : 10.1016/j.jhep.2004.12.027

R. Gish and S. Locarnini, Chronic Hepatitis B: Current Testing Strategies, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.666-76, 2006.
DOI : 10.1016/j.cgh.2006.03.017

J. Pawlotsky, Use and interpretation of virological tests for hepatitis C, Hepatology, vol.24, issue.S1, pp.65-73, 2002.
DOI : 10.1002/hep.1840360709

C. Chen, H. Yang, J. Su, C. Jen, S. You et al., Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA, vol.295, issue.1, pp.65-73, 2006.
DOI : 10.1001/jama.295.1.65

S. Whalley, J. Murray, D. Brown, G. Webster, V. Emery et al., Kinetics of Acute Hepatitis B Virus Infection in Humans, The Journal of Experimental Medicine, vol.69, issue.7, pp.847-54, 2001.
DOI : 10.1002/hep.1840010502

S. Chevaliez, M. Bouvier-alias, S. Laperche, and J. Pawlotsky, Performance of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification, Journal of Clinical Microbiology, vol.46, issue.5, pp.1716-1739, 2008.
DOI : 10.1128/JCM.01248-07
URL : https://hal.archives-ouvertes.fr/inserm-00287220

V. Thibault, C. Pichoud, C. Mullen, J. Rhoads, J. Smith et al., Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections, Journal of Clinical Microbiology, vol.45, issue.12, pp.3948-53, 2007.
DOI : 10.1128/JCM.01180-07

S. Chevaliez, M. Bouvier-alias, R. Brillet, and J. Pawlotsky, Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method, Hepatology, vol.44, issue.1, pp.22-31, 2007.
DOI : 10.1002/hep.21656

S. Chevaliez, M. Bouvier-alias, and J. Pawlotsky, Performance of the Abbott m2000SP/m2000RT real-time polymerase chain reaction assay for hepatitis C virus RNA quantification

R. Sertoz, S. Erensoy, S. Pas, U. Akarca, F. Ozgenc et al., Comparison of Sequence Analysis and INNO-LiPA HBV DR Line Probe Assay in Patients with Chronic Hepatitis B, Journal of Chemotherapy, vol.38, issue.5, pp.514-534, 2005.
DOI : 10.1016/S0168-8278(01)00283-5

M. Hussain, C. Chu, E. Sablon, and A. Lok, Rapid and Sensitive Assays for Determination of Hepatitis B Virus (HBV) Genotypes and Detection of HBV Precore and Core Promoter Variants, Journal of Clinical Microbiology, vol.41, issue.8, pp.3699-705, 2003.
DOI : 10.1128/JCM.41.8.3699-3705.2003

F. Bouchardeau, J. Cantaloube, S. Chevaliez, C. Portal, A. Razer et al., Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay, Journal of Clinical Microbiology, vol.45, issue.4, pp.1140-1145, 2007.
DOI : 10.1128/JCM.01982-06
URL : https://hal.archives-ouvertes.fr/hal-01076948

S. Chevaliez, M. Bouvier-alias, C. Vandervenet, and J. Pawlotsky, HCV genotype determination in clinical practice: weaknesses of assays based on the 5 noncoding region ? and improvement with the core-coding region, Hepatology, vol.46, p.839, 2007.

E. Stelzl, C. Van-der-meer, R. Gouw, M. Beld, M. Grahovac et al., Abstract, Clinical Chemical Laboratory Medicine, vol.45, issue.2, pp.167-70, 2007.
DOI : 10.1515/CCLM.2007.043

J. Verbeeck, M. Stanley, J. Shieh, L. Celis, E. Huyck et al., Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0, Journal of Clinical Microbiology, vol.46, issue.6, pp.1901-1907, 2008.
DOI : 10.1128/JCM.02390-07

J. Pawlotsky, G. Dusheiko, A. Hatzakis, D. Lau, G. Lau et al., Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach, Gastroenterology, vol.134, issue.2, pp.405-420, 2008.
DOI : 10.1053/j.gastro.2007.11.036

A. Gintowt, J. Germer, P. Mitchell, and J. Yao, Evaluation of the MagNA Pure LC used with the TRUGENE??? HBV Genotyping Kit, Journal of Clinical Virology, vol.34, issue.2, pp.155-162, 2005.
DOI : 10.1016/j.jcv.2005.05.008

E. Libbrecht, J. Doutreloigne, H. Van-de-velde, M. Yuen, C. Lai et al., Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay, Journal of Clinical Microbiology, vol.45, issue.12, pp.3935-3976, 2007.
DOI : 10.1128/JCM.00020-07

C. Osiowy, J. Villeneuve, E. Heathcote, E. Giles, and J. Borlang, Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2), Journal of Clinical Microbiology, vol.44, issue.6, pp.1994-2001, 2006.
DOI : 10.1128/JCM.02477-05

E. Keeffe, D. Dieterich, S. Han, I. Jacobson, P. Martin et al., A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update, Clinical Gastroenterology and Hepatology, vol.4, issue.8, pp.936-62, 2006.
DOI : 10.1016/j.cgh.2006.05.016

A. Lok, Chronic Hepatitis B, New England Journal of Medicine, vol.346, issue.22, pp.1682-1685, 2002.
DOI : 10.1056/NEJM200205303462202

A. Lok and B. Mcmahon, Chronic hepatitis B: Update of recommendations, Hepatology, vol.36, issue.3, pp.857-61, 2004.
DOI : 10.1002/hep.20110

D. Prati, E. Taioli, A. Zanella, D. Torre, E. Butelli et al., Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels, Annals of Internal Medicine, vol.137, issue.1, pp.1-10, 2002.
DOI : 10.7326/0003-4819-137-1-200207020-00006

U. Iloeje, H. Yang, J. Su, C. Jen, S. You et al., Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, Gastroenterology, vol.130, issue.3, pp.678-86, 2006.
DOI : 10.1053/j.gastro.2005.11.016

C. Chen, H. Yang, J. Su, C. Jen, S. You et al., 141 SERIAL MONITORING OF VIRAL LOAD AND SERUM ALANINE AMINOTRANFERASE LEVEL AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC): R.E.V.E.A.L.-HBV STUDY UPDATE, Journal of Hepatology, vol.48, issue.2, p.61, 2008.
DOI : 10.1016/S0168-8278(08)60143-9

C. Lai and M. Yuen, The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points, Annals of Internal Medicine, vol.147, issue.1, pp.58-61, 2007.
DOI : 10.7326/0003-4819-147-1-200707030-00010

A. Lok and B. Mcmahon, Chronic hepatitis B, Hepatology, vol.4, issue.RR-16, pp.507-546, 2007.
DOI : 10.1002/hep.21513

A. Lok, D. Chien, Q. Choo, T. Chan, E. Chiu et al., Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients, Hepatology, vol.325, issue.3, pp.497-502, 1993.
DOI : 10.1002/hep.1840180305

C. Thio, K. Nolt, J. Astemborski, D. Vlahov, K. Nelson et al., Screening for hepatitis C virus in human immunodeficiency virus-infected individuals, J Clin Microbiol, vol.38, pp.575-582, 2000.

J. Sanchez-tapias, M. Diago, P. Escartin, J. Enriquez, M. Romero-gomez et al., Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment, Gastroenterology, vol.131, issue.2, pp.451-60, 2006.
DOI : 10.1053/j.gastro.2006.05.016

O. Dalgard, K. Bjoro, K. Hellum, B. Myrvang, S. Ritland et al., Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study, Hepatology, vol.38, issue.Suppl 1, pp.1260-1265, 2004.
DOI : 10.1002/hep.20467

P. Ferenci, U. Bergholz, H. Laferl, T. Scherzer, A. Maieron et al., 8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS??) plus ribavirin (COPEGUS??) in HCV genotype 1 or 4 ???super-responders???, Journal of Hepatology, vol.44, p.6, 2006.
DOI : 10.1016/S0168-8278(06)80009-7

A. Andriulli, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3, N Engl J Med, vol.352, pp.2609-2626, 2005.

M. Von-wagner, M. Huber, T. Berg, H. Hinrichsen, J. Rasenack et al., Peginterferon-??-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C, Gastroenterology, vol.129, issue.2, pp.522-529, 2005.
DOI : 10.1053/j.gastro.2005.05.008

S. Zeuzem, M. Buti, P. Ferenci, J. Sperl, Y. Horsmans et al., Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia, Journal of Hepatology, vol.44, issue.1, pp.97-103, 2006.
DOI : 10.1016/j.jhep.2005.10.003

M. Fried, S. Hadziyannis, M. Shiffman, D. Messinger, and S. Zeuzem, 7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION, Journal of Hepatology, vol.48, issue.2, pp.5-6, 2008.
DOI : 10.1016/S0168-8278(08)60009-4